Analysis Of The Relationship Of Covid-19 Symptoms Which Receive Favipiravir And Length Of Treatment In The Inpatition Of Dr. Iskak Tulungagung
DOI:
https://doi.org/10.59188/eduvest.v4i5.1277Keywords:
Favipiravir, COVID-19, Moderate SymptomsAbstract
Coronavirus disease 2019 or commonly called COVID-19 is an infectious disease caused by SARS-CoV-2. Favipiravir is a broad-spectrum antiviral drug so it has potential antiviral action against SARS-CoV-2 which is an RNA virus. This research aims to find out the relationship between Covid-19 symptoms when receiving favipiravir and the length of treatment of patients hospitalized at RSUD Dr. Iskak Tulungagung. Observational research with descriptive retrospective methods in COVID-19 patients' moderate symptoms with Favipiravir therapy at RSUD dr. Iskak Tungagung period July - September 2021. Data collection using the calculation of the Slovin formula to determine the number of patient samples. Analysis analysis using SPSS by carrying out the Chi-square test. The results of the study were obtained from 146 patients, the pattern of using Favipiravir was given at a dose (2x1600mg) on the first day followed by (2x600mg) on the second day and so on with the most giving range of 1-7 days .
References
Annisa, D. (2021). Situasi Terkini Perkembangan Coronavirus Disease (COVID-19) 18 Juli 2021. Https://Infeksiemerging.Kemkes.Go.Id.
Bajgain, K. T., Badal, S., Bajgain, B. B., & Santana, M. J. (2021). Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. American Journal of Infection Control, 49(2), 238–246. https://doi.org/10.1016/j.ajic.2020.06.213
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Ju, L., Zhang, J., & Wang, X. (2020). Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. MedRxiv. https://doi.org/10.1101/2020.03.17.20037432
Dong, L., Hu, S., & Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries & Therapeutics, 14(1), 58–60. https://doi.org/10.5582/ddt.2020.01012
Du, Y. X., & Chen, X. P. (2020). Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. In Clinical Pharmacology and Therapeutics (Vol. 108, Issue 2). https://doi.org/10.1002/cpt.1844
Guo, C. X., He, L., Yin, J. Y., Meng, X. G., Tan, W., Yang, G. P., Bo, T., Liu, J. P., Lin, X. J., & Chen, X. (2020). Epidemiological and clinical features of pediatric COVID-19. BMC Medicine, 18(1), 1–7. https://doi.org/10.1186/s12916-020-01719-2
Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., & Martinez-de-Hoyo, R. (2021). The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Scientific Reports, 11(1), 1–11. https://doi.org/10.1038/s41598-021-90551-6
Kementrian Kesehatan Republik Indonesia. (2020). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MenKes/413/2020 Tentang Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019 (Covid-19). MenKes/413/2020, 2019, 207.
Keputusan Menteri Kesehatan Republik Indonesia. (2021). Keputusan menteri kesehatan republik indonesia nomor hk.01.07/menkes/5671/2021 tentang manajemen klinis tata laksana. 3, 1–106.
Mi, J., Zhong, W., Huang, C., Zhang, W., Tan, L., & Ding, L. (2020). Gender, age and comorbidities as the main prognostic factors in patients with COVID-19 pneumonia. American Journal of Translational Research, 12(10), 6537–6548.
Mukherjee, S., & Pahan, K. (2021). Is COVID-19 Gender-sensitive? 38–47.
PDPI, PERKI, PAPDI, PERDATIN, & IDAI. (2020). Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. In Pedoman Tatalaksana COVID-19.
Skrip, L. A., Selvaraj, P., Hagedorn, B., Ouédraogo, A. L., Noori, N., Orcutt, A., Mistry, D., Bedson, J., Hébert-Dufresne, L., Scarpino, S. V., & Althouse, B. M. (2021). Seeding COVID-19 across sub-saharan Africa: An analysis of reported importation events across 49 countries. American Journal of Tropical Medicine and Hygiene, 104(5), 1694–1702. https://doi.org/10.4269/ajtmh.20-1502
Solaymani-Dodaran, M., Ghanei, M., Bagheri, M., Qazvini, A., Vahedi, E., Hassan Saadat, S., Amin Setarehdan, S., Ansarifar, A., Biganeh, H., Mohazzab, A., Khalili, D., Hosein Ghazale, A., Reza Heidari, M., Taheri, A., Khoramdad, M., Mahdi Asadi, M., Nazemieh, M., Varshochi, M., Abbasian, S., … Moazen, J. (2021). Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. International Immunopharmacology, 95(March), 107522. https://doi.org/10.1016/j.intimp.2021.107522
Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Herikurniawan, H., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E. J., Chen, L. K., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C. O. M., & Yunihastuti, E. (2020). Coronavirus Disease 2019: Tinjauan Literatur Terkini. Jurnal Penyakit Dalam Indonesia, 7(1), 45. https://doi.org/10.7454/jpdi.v7i1.415
Wang, X., Zhang, H., Du, H., Ma, R., Nan, Y., & Zhang, T. (2021). Risk Factors for COVID-19 in Patients with Hypertension. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021. https://doi.org/10.1155/2021/5515941
WHO. (2021). COVID-19 Weekly Epidemiological Update 35. World Health Organization, December, 1–3.
Published
Issue
Section
License
Copyright (c) 2024 Aghnia Fuadatul Inayah, Ghassani Shabrina Putri, Amaliyah Dina Anggraeni
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
